Adaptive Biotechnologies Q3 revenue up 50% to $39.5M, net loss widens; appoints new principal accounting officer

Adaptive Biotechnologies Corp

2022-Q3 EPS reported -$1.04 revenue$116,414,000

Q3 2021 revenue $39.5M (+50% YoY); sequencing revenue $22.1M (+96%), development revenue $17.4M (+16%).
Net loss $56.0M vs $36.7M in Q3 2020; adjusted EBITDA loss $41.1M vs $28.4M.
Full-year 2021 revenue guidance reaffirmed at $148-155M, ~54% growth at midpoint.
clonoSEQ sequencing volume grew 47% YoY; launched enhanced assay for CLL including IGHV mutation status.
Kyle Piskel appointed principal accounting officer; Chad Cohen remains CFO and principal financial officer.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kyle Piskel

principal accounting officer

ADPT · Adaptive Biotechnologies Corp

Effective: 2021-10-28
Filed: November 3, 2021, 7:59 PM ET

On October 28, 2021, the Board of Directors of the Company designated Kyle Piskel as the Company’s principal accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kyle Piskel was appointed as principal accounting officer at Adaptive Biotechnologies Corp.

Action: designated
Role: principal accounting officer

Exact text from the filing

On October 28, 2021, the Board of Directors of the Company designated Kyle Piskel as the Company’s principal accounting officer.

View on SEC.gov

Adaptive Biotechnologies Corp filing history →

Source: SEC EDGAR

accession 0001564590-21-053963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.